No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
DXR Daxor
- 9.480
- +0.280+3.04%
Close Jul 19 16:00 ET
45.85MMarket Cap67.71P/E (TTM)
9.480High9.460Low1.05KVolume9.460Open9.200Pre Close9.92KTurnover0.05%Turnover Ratio67.71P/E (Static)4.84MShares10.15052wk High1.35P/B19.91MFloat Cap7.11052wk Low--Dividend TTM2.10MShs Float24.076Historical High--Div YieldTTM0.22%Amplitude3.400Historical Low9.473Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Daxor Corporation's BVA-100 Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide
Daxor's ezBVA Lab Service Emerges as Key Driver for Expansion and Market Penetration Oak Ridge, TN, July 11, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume
Express News | Daxor Corporation to Exhibit at AAHFN 20th Annual Meeting, Showcasing Blood Volume Measurement Technology
Daxor Corporation to Showcase the Benefits of BVA-100 Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting
Oak Ridge, TN, June 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today it will exhibit at the American Association of Heart Failure
Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer
Oak Ridge, TN, June 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the appointment of Dr. John L. Jefferies,
Investor's Confidence in German Economy Is Growing -- Market Talk
0855 GMT - Investors' confidence in the German economy has been increasing, even if the data is only now reflecting it, CMC Markets analysts say in a research note. Last week's impressive rally pushed
New Studies Prove the Clinical Benefits of Daxor's Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
Data Presented at the American College of Cardiology Scientific Sessions; Research Letter Published in the Prestigious American Heart Journal Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation
Comments
$Daxor(DXR.US$
Daxor Corporation’s BVA-100™ Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide
Daxor (Nasdaq: DXR) announced the expansion of its blood volume analysis (BVA) technology, including the launch of new BVA programs and the increased adoption of its ezBVA Lab service. This CLIA-certified facility provides next-day blood volume analysis results on-demand. Recent expansions include a regional referral center for Northeast Arkansas and Southeast Missouri...
Daxor Corporation’s BVA-100™ Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide
Daxor (Nasdaq: DXR) announced the expansion of its blood volume analysis (BVA) technology, including the launch of new BVA programs and the increased adoption of its ezBVA Lab service. This CLIA-certified facility provides next-day blood volume analysis results on-demand. Recent expansions include a regional referral center for Northeast Arkansas and Southeast Missouri...
$Daxor(DXR.US$
NEWS
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
Daxor (Nasdaq: DXR) announces two new studies validating the clinical benefits of blood volume analysis (BVA) in ambulatory heart failure patients. The studies highlight the lack of correlation between surrogate measures and actual blood volume, emphasizing the importance of accurate volume measurement. Data presented at th...
NEWS
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
Daxor (Nasdaq: DXR) announces two new studies validating the clinical benefits of blood volume analysis (BVA) in ambulatory heart failure patients. The studies highlight the lack of correlation between surrogate measures and actual blood volume, emphasizing the importance of accurate volume measurement. Data presented at th...
1
Hello everyone,
We're seeking community insights on the potential movement of this stock in the coming one to two months. Do you anticipate it to rise or fall?
If you have any solid ideas, insider information, or news that might influence this stock's direction, kindly share in the comments section below. Your input is greatly valued!
Thank you for your participation.
$Daxor(DXR.US$
We're seeking community insights on the potential movement of this stock in the coming one to two months. Do you anticipate it to rise or fall?
If you have any solid ideas, insider information, or news that might influence this stock's direction, kindly share in the comments section below. Your input is greatly valued!
Thank you for your participation.
$Daxor(DXR.US$
1
$Daxor(DXR.US$ slow and steady volume increase. Microfloat, lots of good news, will be a runner when she gets found
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg